Join

Compare · IXHL vs NVO

IXHL vs NVO

Side-by-side comparison of Incannex Healthcare Inc. (IXHL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both IXHL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $203.51B, about 5077.6x IXHL ($40.1M).
  • Over the past year, IXHL is down 42.4% and NVO is down 39.5% - NVO leads by 2.9 points.
  • NVO has been more active in the news (11 items in the past 4 weeks vs 5 for IXHL).
  • NVO has more recent analyst coverage (25 ratings vs 0 for IXHL).
PerformanceIXHL-42.40%NVO-39.50%
2025-06-02+0.00%2026-06-01
MetricIXHLNVO
Company
Incannex Healthcare Inc.
Novo Nordisk A/S
Price
$3.24-4.42%
$44.05-3.39%
Market cap
$40.1M
$203.51B
1M return
-26.36%
+4.41%
1Y return
-42.40%
-39.50%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
News (4w)
5
11
Recent ratings
0
25
IXHL

Incannex Healthcare Inc.

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Latest IXHL

Latest NVO